Mybl1

Break-apart FISH assay for MYB, NFIB, and MYBL1 (all from Empire Genomics, Buffalo, NY, USA) was performed. ^{10 (link)}
Tumour cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) II (ZytoVision GmbH, Bremerhaven, Germany) after hybridization. ^{12 (link)}

Primary tumor and metastatic lesion were evaluated for rearrangements of MYB (Empire Genomics, Buffalo, NY, USA), MYBL1 (Empire Genomics), and NFIB (Empire Genomics) genes with break-apart probes according to the manufacturer's instructions using the HYBrite platform (Abbott Molecular) and counterstained with DAPI II (ZytoVision GmbH, Bremerhaven, Germany) as previously described [31 (link)]. One hundred nuclei were counted, and only nuclei where the entire nuclear membrane could be visualized were scored. Break-apart signals in ≥ 10% of cells was considered to represent rearrangement [31 (link)]. Amplification was defined as a red/green or green/red signal ratios ≥ 2 signals for 3′ and 5′ amplification, respectively. Amplification was defined as a red/green or green/red signal ratio of ≥ 3 in in more than 10% of tumor cells for 3′ and 5′ amplification, respectively.